Moberg Pharma AB (publ) (STO: MOB)

Market Cap	494.02M
Revenue (ttm)	8.78M
Net Income (ttm)	-18.25M
Shares Out	46.69M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	618,354
Open	10.72
Previous Close	10.68
Day's Range	10.32 - 10.86
52-Week Range	6.34 - 40.90
Beta	0.95
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 11, 2025

About Moberg Pharma AB

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 10
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MOB